Mankind Pharma Q4 FY25: Revenue up 27%, profit down 10%

A busy Q4 results day puts focus on earnings

A long list of Indian companies is scheduled to release January to March quarter numbers on May 19, keeping traders focused on earnings-led moves. The line-up includes large names such as Bharat Electronics, Bharat Petroleum Corporation (BPCL), Zydus Lifesciences, Mankind Pharma, BASF India, PI Industries, Zee Entertainment Enterprises, Bosch Home Comfort India, BLS International Services, and C.E. Info Systems. Several mid and small-cap companies are also slated to report, spanning infrastructure, specialty chemicals, consumer goods, textiles, and financials.

Within this broader results season, Mankind Pharma’s March quarter performance has drawn attention because it combines strong top-line growth with a decline in profit and a softer operating margin. The company’s numbers also include the impact of consolidation of Bharat Serums and Vaccines (BSV), which management referenced during its earnings call.

Companies set to report Q4 results on May 19

The results calendar published for May 19 covers more than 100 names. Alongside the widely tracked companies, the list also includes firms such as PNC Infratech, Fine Organic Industries, Prince Pipes and Fittings, Eureka Forbes, Godawari Power and Ispat, ASK Automotive, Exicom Tele-Systems, Dishman Carbogen Amcis, Dhanuka Agritech, Karnataka Bank, Trident, Safari Industries India, HealthCare Global Enterprises, Borosil, J. Kumar Infraprojects, Orkla India, and Siyaram Silk Mills.

For investors, such clustered reporting days typically increase stock-specific volatility. Price action tends to reflect not only the headline profit or revenue numbers, but also margin movement, management commentary on demand, and updates on acquisitions or portfolio changes.

Mankind Pharma’s headline Q4 picture

For the quarter ended March 2025 (Q4 FY25), Mankind Pharma reported a 27.1% year-on-year rise in revenue from operations to about ₹3,079 crore, compared with about ₹2,422 crore in the year-ago quarter. The company’s profit, however, declined year-on-year. Different reports in the provided material pegged consolidated net profit at ₹420.80 crore, ₹424.65 crore, ₹425.11 crore, and ₹429 crore, each implying roughly a 10% year-on-year decline versus a profit of about ₹471-₹477 crore in Q4 FY24.

Operating performance improved in absolute terms, but profitability ratios tightened. EBITDA for the quarter was reported in the ₹683-₹686 crore range, while EBITDA margin was cited at about 22.2%-22.3%, down from about 24.2%-24.3% a year earlier.

What management highlighted about the quarter

In the earnings commentary included in the provided text, vice-chairman and managing director Rajeev Juneja said the company achieved healthy revenue growth in Q4. He linked the performance to strong growth in chronic therapies, a recovery in the consumer segment, and consolidation of Bharat Serums and Vaccines.

The company also highlighted that Q4 FY25 was the first full quarter of BSV results, and that FY25 included 160 days of BSV financial performance. This matters for comparability because consolidation can lift revenue while also adding integration-related costs and higher depreciation and finance costs.

Segment and geography cues: domestic, exports, and consumer health

On the domestic front, Mankind reported an 18% year-on-year rise in domestic business revenues to ₹2,544 crore in Q4 FY25 from ₹2,155 crore in Q4 FY24. Management commentary referred to chronic therapies and contributions from the acquired portfolio as key drivers.

Exports were a standout in percentage terms. The export business was reported to have grown 100% year-on-year in the March quarter, with exports of ₹535 crore cited in one summary. Consumer healthcare revenue growth of 14% in Q4 was also mentioned across the provided material.

Full-year FY25: scale-up and mix changes

For the full year, Mankind’s revenue was reported at ₹12,207 crore, up 19% from ₹10,260 crore in FY24. Adjusted EBITDA for FY25 was cited at ₹3,159 crore with a margin of 25.9%. Domestic revenue crossed ₹10,000 crore for FY25, reaching ₹10,675 crore, up 13% year-on-year.

Exports for the full year were reported at ₹1,532 crore, reflecting an 88% jump over FY24. Gross margin expansion was also mentioned, with full-year gross margin reported at 71.4% versus 68.8% in FY24 in the earnings call excerpts.

Key numbers at a glance

Stock reaction: intraday dip amid mixed print

Mankind Pharma’s stock reaction reflected the mixed set of numbers. One market update said that at around 12:05 PM, the stock traded 3.57% lower at ₹2,441 on the NSE versus a previous close of ₹2,531.40, with an intraday high of ₹2,484.80 and a low of ₹2,430.

Another update in the provided material said the shares closed 0.75% lower at about ₹2,530, and also noted a marginal decline of 0.69% to ₹2,533.03 on the BSE on the day the company declared results after market hours. These snapshots indicate a cautious response as investors weighed strong revenue momentum against profit decline and margin contraction.

Why the numbers matter for investors

Mankind’s Q4 FY25 results underline a key market theme in this earnings season: strong top-line growth is not always translating into higher profits. In this case, the provided material linked profit pressure to higher finance cost and depreciation cost following full-quarter consolidation of BSV.

The split between domestic growth, consumer health traction, and a sharp rise in exports offers investors more data points on the company’s growth mix. At the same time, the lower EBITDA margin versus last year suggests that investors may focus closely on how margins evolve as consolidation effects stabilise.

Conclusion

Mankind Pharma delivered strong Q4 FY25 revenue growth of about 27% and reported gains in domestic revenue and exports, but profit fell about 10% and margins narrowed compared with last year. With many large and mid-cap names reporting around the same period, investors are likely to track management commentary and subsequent filings for clearer read-through on costs, margins, and integration of BSV.